Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Nationwide Children's Hospital - Infectious Diseases
mi
from
Columbus, OH
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Nationwide Children's Hospital - Infectious Diseases
mi
from
Columbus, OH
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Hospital of Pittsburgh of UPMC - Pediatric Infectious Diseases
mi
from
Pittsburgh, PA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Hospital of Pittsburgh of UPMC - Pediatric Infectious Diseases
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Rhode Island Hospital - Pediatrics
mi
from
Providence, RI
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Rhode Island Hospital - Pediatrics
mi
from
Providence, RI
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Medical University of South Carolina - Pediatrics - Infectious Diseases
mi
from
Charleston, SC
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Medical University of South Carolina - Pediatrics - Infectious Diseases
mi
from
Charleston, SC
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Vanderbilt University - Pediatric - Infectious Diseases
mi
from
Nashville, TN
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Vanderbilt University - Pediatric - Infectious Diseases
mi
from
Nashville, TN
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Children's Medical Center Dallas - Neonatal ICU
mi
from
Dallas, TX
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Children's Medical Center Dallas - Neonatal ICU
mi
from
Dallas, TX
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Texas Southwestern Medical Center - Pediatrics
mi
from
Dallas, TX
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Texas Southwestern Medical Center - Pediatrics
mi
from
Dallas, TX
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Cook Children's Infectious Disease Services
mi
from
Fort Worth, TX
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Cook Children's Infectious Disease Services
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
University of Utah - Pediatric Pharmacology Program
mi
from
Salt Lake City, UT
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
University of Utah - Pediatric Pharmacology Program
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Seattle Children's Hospital - Infectious Diseases
mi
from
Seattle, WA
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Seattle Children's Hospital - Infectious Diseases
mi
from
Seattle, WA
Click here to add this to my saved trials
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated:  8/13/2015
Bristol Royal Hospital for Children - UBHT Education Centre
mi
from
Bristol,
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status: Enrolling
Updated: 8/13/2015
Bristol Royal Hospital for Children - UBHT Education Centre
mi
from
Bristol,
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Valrico, FL
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Valrico, FL
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Hinsdale, IL
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Kansas City, MO
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
New York, NY
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
Blue Bell, PA
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated:  8/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing
Status: Enrolling
Updated: 8/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated:  8/14/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated: 8/14/2015
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated:  8/14/2015
Oregon Health and Science University
mi
from
Portland, OR
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated: 8/14/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated:  8/14/2015
UT Southwestern Medical Center
mi
from
Dallas, TX
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated: 8/14/2015
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated:  8/14/2015
The University of Texas, Houston
mi
from
Houston, TX
Angel® Catheter Early Feasibility Clinical Study
A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism
Status: Enrolling
Updated: 8/14/2015
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
Status: Enrolling
Updated:  8/19/2015
Massachusetts General Hospital
mi
from
Boston, MA
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
Status: Enrolling
Updated: 8/19/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Genetic Variability and Biomarkers in Children With Acute Lung Injury
Genetic Variability and Biomarkers in Children With Acute Lung Injury
Status: Enrolling
Updated:  8/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Genetic Variability and Biomarkers in Children With Acute Lung Injury
Genetic Variability and Biomarkers in Children With Acute Lung Injury
Status: Enrolling
Updated: 8/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery
A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery
Status: Enrolling
Updated:  8/22/2015
Washington University School of Medicine and Barnes Jewish Hospital
mi
from
St Louis, MO
A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery
A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery
Status: Enrolling
Updated: 8/22/2015
Washington University School of Medicine and Barnes Jewish Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
Status: Enrolling
Updated:  8/24/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
Status: Enrolling
Updated: 8/24/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
Status: Enrolling
Updated:  8/24/2015
UCSD Medical Center, Division of Neurosurgery
mi
from
San Diego, CA
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
Status: Enrolling
Updated: 8/24/2015
UCSD Medical Center, Division of Neurosurgery
mi
from
San Diego, CA
Click here to add this to my saved trials
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
Status: Enrolling
Updated:  8/25/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
Status: Enrolling
Updated: 8/25/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Burn Micronutrient Repletion Pilot Study
Burn Micronutrient Repletion Pilot Study: Characterizing Relationships Between Vitamin and Mineral Supplementation and Health Outcomes of Adult Burn Patients
Status: Enrolling
Updated:  8/25/2015
Memorial Medical Center
mi
from
Springfield, IL
Burn Micronutrient Repletion Pilot Study
Burn Micronutrient Repletion Pilot Study: Characterizing Relationships Between Vitamin and Mineral Supplementation and Health Outcomes of Adult Burn Patients
Status: Enrolling
Updated: 8/25/2015
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Christiana Care Health System
mi
from
Newark, DE
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Christiana Care Health System
mi
from
Newark, DE
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Baystate Medical Center
mi
from
Springfield, MA
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Division of Education and Research SMDC Health System
mi
from
Duluth, MN
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Division of Education and Research SMDC Health System
mi
from
Duluth, MN
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Cooper University Hospital
mi
from
Camden, NJ
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Cooper University Hospital
mi
from
Camden, NJ
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Baylor College of Medicine
mi
from
Houston, TX
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated:  8/26/2015
Clinique Universitaire St-Luc
mi
from
Brussels,
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock
Status: Enrolling
Updated: 8/26/2015
Clinique Universitaire St-Luc
mi
from
Brussels,
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Veterans' Affairs Medical Center
mi
from
Birmingham, AL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Veterans' Affairs Medical Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Cardiovascular Consultants - Thunderbird
mi
from
Glendale, AZ
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Cardiovascular Consultants - Thunderbird
mi
from
Glendale, AZ
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Cardiovascular Consultants - Phoenix
mi
from
Phoenix, AZ
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Cardiovascular Consultants - Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Orthoarkansas
mi
from
Little Rock, AR
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Orthoarkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Comprehensive Cardiovascular Specialists
mi
from
Alhambra, CA
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Comprehensive Cardiovascular Specialists
mi
from
Alhambra, CA
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
St Joseph's Medical Center
mi
from
Stockton, CA
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
St Joseph's Medical Center
mi
from
Stockton, CA
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Colorado Heart & Vascular
mi
from
Denver, CO
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Colorado Heart & Vascular
mi
from
Denver, CO
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Okaloosa Heart & Vascular
mi
from
Crestview, FL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Okaloosa Heart & Vascular
mi
from
Crestview, FL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Infinity-Northshore
mi
from
Fort Lauderdale, FL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Infinity-Northshore
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Infinity Clinical Research, LLC
mi
from
Hollywood, FL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Infinity Clinical Research, LLC
mi
from
Hollywood, FL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Heart Rhythm Specialists
mi
from
Naples, FL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Heart Rhythm Specialists
mi
from
Naples, FL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Cardiology of Atlanta
mi
from
Atlanta, GA
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Cardiology of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated:  8/27/2015
Grady Hospital
mi
from
Atlanta, GA
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Status: Enrolling
Updated: 8/27/2015
Grady Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials